Understanding the costs of drug-related actions is an important aspect of drug policy. Some of the funds allocated by governments to expenditure on tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, most drug-related expenditure is not identified (‘unlabelled’) and must be estimated using modelling approaches. Although the financing of drug-related activities in Bulgaria is decided annually by the entities in charge of their implementation, coordination between central and local government plays an important role. Estimates for drug-related public expenditure are reported. Preliminary estimates indicate that, in 2015, a total of BGN 3 892 496 (EUR 1 990 232) was allocated for labelled drug-related expenditure, which amounted to about 0.01 % of gross domestic product.